71 search results for lung cancer
Clinical Guidelines Translations
(Arabic) Non-Small Cell Lung Cancer Version 3.2023 (Arabic) Ovarian Cancer, ) Esophageal and Esophagogastric Junction Cancers Version 3.2022 (Chinese) Gastric Cancer, (Chinese) Small Cell Lung Cancer Version 1.2023 (Chinese) T-Cell Lymphomas, Lung Cancer Version 3.2022 (French) Pediatric Acute Lymphoblastic Leukemia Version, (Italian) Multiple Myeloma Version 5.2022 (Italian) Non-Small Cell Lung Cancer
https://www.nccn.org/global/what-we-do/clinical-guidelines-translationsGuidelines for Patients Translations
for Patients® Non-Small Cell Lung Cancer - Early and Locally Advanced Version 2024 (Arabic) Guidelines for Patients® Non-Small Cell Lung Cancer - Metastatic Version 2024 (Arabic, Lung Cancer Version 2024 (Arabic) Guidelines for Patients® Uterine Cancer Version 2023, Cell Lung Cancer - Early and Locally Advanced Version 2024 (Chinese) Guidelines for Patients® Non-Small Cell Lung Cancer - Metastatic Version 2024 (Chinese) Guidelines
https://www.nccn.org/global/what-we-do/guidelines-for-patients-translationsNCCN's Response to S.689/H.1074 An Act Relative to Patient Access to Biomarker Testing to Provide Appropriate Therapy
-Concordant Treatment for Lung Cancer in the United States. Ann Am Thorac Soc. 2020 Feb;l7(2):186-194, National Comprehensive Cancer Network "' April 25, 2023 Robert W. Carlson, MD Chief, appropriate therapy Dear Chair Feeney and Chair Murphy: The National Comprehensive Cancer Network, , and accessible cancer care. NCCN will focus our supportive comments on the impo1tance, r i g h a m a n d W o m e n ' s C a n c e r Center I Massachusetts General Hospital Cancer Center
https://www.nccn.org/docs/default-source/oncology-policy-program/access/nccn-letter-of-support-ma-s-689h-1074.pdf?sfvrsn=14ea90dd_3International Adaptations
Cell Lung Cancer Version 3.2022 (English) Ovarian Cancer/Fallopian Tube Cancer/Primary, Breast Cancer Version 4.2023 (English) Central Nervous System Cancers, Cancer Version 2.2022 (English) Head and Neck Cancers Version 2.2022 (English, country/region at this time. Brazil Editions Prostate Cancer Version 4.2024 (English) China Editions Cervical Cancer Version 1.2023 (English
https://www.nccn.org/global/what-we-do/international-adaptationsClinical Trials
in advanced refractory gastric cancer patients Gynecological Cancers Siqing Fu MD PhD, Microsatellite Stable Endometrial Carcinoma Head and Neck Cancers Aarti Bhatia, MD, MPH Yale Cancer, for AML Relapse after Allogenic Hematopoietic Cell Transplantation Lung Cancer Yasir Elamin, MD, Select a cancer below for additional information on ORP active trials at NCCN Member Institutions. Gastrointestinal Scott Plotkin, MD Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts
https://www.nccn.org/education-research/nccn-oncology-research-program/clinical-trialsPermission to Cite or Use NCCN Content
Cell Skin Cancer B-Cell Lymphomas Biliary Tract Cancers Bladder Cancer Bone Cancer Breast Cancer, Nervous System Cancers Cervical Cancer Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Distress Management Esophageal and Esophagogastric Junction Cancers Gastric Cancer Gastrointestinal, Hodgkin Lymphoma Kaposi Sarcoma Kidney Cancer Lung Cancer Screening Management of Immunotherapy, Neuroendocrine and Adrenal Tumors Non-Small Cell Lung Cancer Occult Primary Older Adult Oncology
https://www.nccn.org/guidelines/permission-to-cite-or-use-nccn-contentRecently Updated Guidelines
Lung Cancer Version 11.2024 Penile Cancer Version 1.2025 Small Cell Lung Cancer, with Evidence Blocks - Non-Small Cell Lung Cancer Version 11.2024 NCCN Guidelines with Evidence, Lung Cancer Version 3.2025 NCCN Guidelines with Evidence Blocks - Testicular Cancer Version, High-Risk Assessment: Colorectal, Endometrial, and Gastric Version 3.2024 Lung Cancer, of Cancer by Type Bladder Cancer Version 5.2024 Breast Cancer Version 5.2024
https://www.nccn.org/guidelines/recently-published-guidelinesGuidelines Panels
Lung Cancer Screening Panel, Panel Non-Small Cell Lung Cancer, Small Cell Lung Cancer Panel, Adult Cancer Pain Panel, Bladder/Penile Cancers Panel
https://www.nccn.org/guidelines/guidelines-panels-and-disclosure/disclosure-panelsResume Screening
Carcinoma Basal Cell Skin Cancer B-Cell Lymphomas Biliary Tract Cancers Bladder Cancer Bone Cancer Breast Cancer Castleman Disease Central Nervous System Cancers Cervical Cancer Chronic, Dermatofibrosarcoma Protuberans Esophageal and Esophagogastric Junction Cancers Gastric Cancer Gastrointestinal, Neuroendocrine and Adrenal Tumors Non-Small Cell Lung Cancer Occult Primary Ovarian Cancer, Cancers Pediatric Hodgkin Lymphoma Penile Cancer Primary Cutaneous Lymphomas Prostate Cancer Rectal
https://www.nccn.org/covid-19/resume-screeningHarmonized Guidelines
5.2022 Biliary Tract Cancers Version 3.2023 Bladder Cancer Version 1.2023, Cancers Version 2.2022 Cervical Cancer Version 1.2023 Chronic Lymphocytic, Colon Cancer Version 2.2022 Esophageal and Esophagogastric Junction Cancers Version, and Adrenal Tumors Version 1.2022 Non-Small Cell Lung Cancer Version 4.2024 Occult, Pediatric Central Nervous System Cancers Version 2.2023 Penile Cancer Version
https://www.nccn.org/global/what-we-do/harmonized-guidelinesORP Grant History
lung cancer AstraZeneca Pharmaceuticals, LP – quality improvement/ projects in ovarian cancer AstraZeneca Pharmaceuticals, LP – quality improvement/ projects in small cell lung cancer AstraZeneca Pharmaceuticals, LP – quality improvement/ projects in early stage non-small cell lung cancer AVEO, of combination therapies with afatinib in lung cancer Bristol-Myers Squibb Company and ImClone, of carboplatin, pemetrexed, and bevaciumab, with or without atezolizumab, in lung cancer
https://www.nccn.org/education-research/nccn-oncology-research-program/orp-grant-historyGuidelines for Patients
Version: 2022 Non-Small Cell Lung Cancer - Early, -Small Cell Lung Cancer - Metastatic Version: 2024, Cell Lung Cancer Version: 2024 Soft, Lung Cancer Screening Version: 2023, patient help, breast cancer patient, breast cancer resources, prostate cancer resources, lung cancer
https://www.nccn.org/patientresources/patient-resources/guidelines-for-patientsTransparency Process
Lung Cancer Screening Panel Version: 1.2025 ( Lung Cancer Screening ) Date: 2024-06-18 Transparency Panel Disclosures/Attendance, Adult Cancer Pain Panel Version: 2.2024 ( Adult Cancer Pain, ( Adult Cancer Pain ) Date: 2023-09-28 Transparency Panel Disclosures/Attendance Version: 1.2023 ( Adult Cancer Pain ) Date: 2022-09-12 Transparency Panel Disclosures
https://www.nccn.org/guidelines/guidelines-process/transparency-process-and-recommendationsAsia
for Gynecologic Cancers, including cervical Cancer, Ovarian Cancer, Uterine Neoplasms, Gestational Trophoblastic, for the treatment of lung cancer for patients in Vietnam. Moving forward, the groups plan to address the top, Non-Small Cell Lung Cancer Version 3.2023 (English) Non-Small Cell Lung Cancer Version 3.2023, the Press Release | Visit nccnchina.org.cn Chinese Gynecologic Cancer Society (CGCS): In collaboration with the Chinese Gynecologic Cancer Society (CGCS) and Shanghai Yanxin Cultural Firm, NCCN will work
https://www.nccn.org/global/global-program/asiaOncology Research Program (ORP)
: Phase I/II Clinical Trials of Zipalertinib (CLN 081/TAS 6417) for Non-Small Cell Lung Cancers, Research Program (ORP) celebrates 25 years of advancing cancer science! Learn More NCCN ORP, of patients with cancer. Guiding Principles: Study both FDA-approved and investigational agents/devices, to seek novel enhanced, effective, and efficient cancer therapy. Develop new insights into cancer care delivery outcomes and quality, as well as identify solutions to barriers affecting optimal cancer
https://www.nccn.org/education-research/nccn-oncology-research-program/orp-main-pageNCCN Guidelines for Patients with Permission Email
Myeloid Leukemia Colon Cancer Esophageal Cancer Head and Neck Cancers: Nasopharyngeal Cancer Oral Cancers Oropharyngeal Cancer Hepatobiliary Cancers: Liver Cancer Gallbladder and Bile Duct Cancers Hodgkin Lymphoma Kidney Cancer Lung Cancer: Early and Locally Advanced Metastatic Malignant, e a a n d Vomiting Cancer Screening Lung Cancer Screening Age-Related Adolescents and Yo u n g, Invasive Metastatic Colon Cancer Kidney Cancer Lung Cancer: Early and Locally Advanced
https://www.nccn.org/docs/default-source/patient-resources/nccn-guidelines-for-patients-with-permission-email.pdf?sfvrsn=94769ebd_2Young Investigator Awards
Cancers Zachary Frosch, MD, MSHP, Fox Chase Cancer Center Developing Patient-Centered, Institute Intervention Mapping to Improve Lung Cancer Screening Among Black Veterans Ravi, in Patients with Small Cell Lung Cancer Shivan Mehta, MD, MBA, MSHP, Assistant Professor, . News Details The National Comprehensive Cancer Network® (NCCN, NCCN Member Institutions represent tomorrow’s leaders for advancing cancer care. The NCCN Oncology
https://www.nccn.org/education-research/nccn-oncology-research-program/young-investigator-awardsYoung Investigator Awards
and Esophagogastric Cancers Zachary Frosch, MD, MSHP, Fox Chase Cancer Center Developing Patient-Centered, to Improve Lung Cancer Screening Among Black Veterans Ravi Parikh, MD, MPP, The Abramson Cancer, with Small Cell Lung Cancer Shivan Mehta, MD, MBA, MSHP, Assistant Professor of Medicine, The National Comprehensive Cancer Network® (NCCN®) and the NCCN Foundation® each, tomorrow’s leaders for advancing cancer care. The NCCN Oncology Research Program (ORP) manages
https://www.nccn.org/patientresources/patient-resources/nccn-foundation/young-investigator-awardsWebinars for Patients
to view afterward. Upcoming Live Webinars Non-Small Cell Lung Cancer (NSCLC) - Friday, January 17, 2025, ) Small Cell Lung Cancer (2022) 3025 Chemical Road, Suite 100, , webinar, patient resources, breast cancer, lung cancer, recorded webinars, recorded patient webinar, NCCN provides free webinars for people affected by cancer and caregivers. These live, ) (2024) Myeloproliferative Neoplasms (MPN) (2024) Breast Cancer Screening (2024) Advanced
https://www.nccn.org/patientresources/patient-resources/patient-webinarsNCCN History
for the treatment of cancer and perform outcomes research – and so the NCCN was born. With 13 original NCCN, to people with cancer across the country. NCCN became a developer and promoter of national programs, , and patient care. Now an alliance of 33 of the leading cancer centers, NCCN develops and communicates, for the treatment of cancer and perform outcomes research 1995 – Bruce R. Ross leads NCCN as Chief, for the following disease types: Acute Leukemia and Breast, Colon, Lung, Ovarian, Pediatric
https://www.nccn.org/home/about/nccn-history